本文已被：浏览 421次 下载 300次
投稿时间：2022-04-21 网络发布日期：2022-09-20
投稿时间：2022-04-21 网络发布日期：2022-09-20
中文摘要: 目的 探讨初诊弥漫性大B细胞淋巴瘤（DLBCL）患者使用国产利妥昔单抗（汉利康）治疗的近期疗效及安全性。方法 收集2019年7月至2021年3月安徽医科大学第二附属医院血液科明确诊断并采用国产利妥昔单抗为基础化疗方案治疗的14例初诊DLBCL患者的临床资料。化疗3~4个周期后评估临床疗效，每个化疗周期均进行不良事件评估，检测化疗前后患者外周血免疫球蛋白G（IgG）水平和CD20+B淋巴细胞百分比。结果 所有患者均接受3~8个疗程的化疗，中位化疗周期为6个疗程。化疗3~4个疗程后，7例（50.0%）患者完全缓解，6例（42.9%）患者部分缓解，总体反应率为92.9%。所有患者均未出现急性输液反应、胃肠道不良反应，仅1例患者首次化疗期间出现一过性房性早搏，1例出现转氨酶升高；有10例患者在治疗过程中出现不同程度的血液学毒性，其中2例为4级骨髓抑制，经积极对症治疗均获得逆转缓解。9例患者在化疗前后外周血CD20+B淋巴细胞中位数分别为11.6%和0.0%，差异有统计学意义（Z=2.666，P=0.008）。11例患者在化疗前后外周血IgG水平中位数分别为10.35 g/L和8.56 g/L，差异有统计学意义（Z=2.312，P=0.021）。结论 以国产利妥昔单抗为基础的化疗方案治疗初诊DLBCL的近期疗效及安全性均较好，较原研利妥昔单抗更加经济实惠，且外周血IgG及CD20+B淋巴细胞的变化也反映了国产利妥昔单抗的靶向治疗作用
中文关键词: 弥漫性大B细胞淋巴瘤 国产利妥昔单抗 近期疗效 不良反应
Abstract:Objective To investigate the short-term efficacy and safety of domestic rituximab (Hanlikang?) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Methods The clinical data of 14 newly diagnosed DLBCL patients who were definitely diagnosed and treated with domestic rituximab-based chemotherapy in the Department of Hematology, the Second Affiliated Hospital of Anhui Medical University from July 2019 to March 2021 were collected. The clinical efficacy was evaluated after 3-4 courses of chemotherapy. Adverse events were evaluated in each chemotherapy course. The level of peripheral blood immunoglobulin G (IgG) and the percentage of CD20+B lymphocytes were detected before and after chemotherapy. Results All patients received 3-8 courses of chemotherapy, with a median chemotherapy cycle of 6 courses. After 3-4 courses of chemotherapy, 7 patients (50%) had complete remission and 6 patients (42.9%) had partial remission, and the overall response rate was 92.9%. All patients did not have acute infusion reaction and gastrointestinal adverse reaction, only one patient had transient atrial tachycardia during the first chemotherapy, and one patient had elevated transaminase. There were 10 patients with hematological toxicity of different degrees during the treatment, including 2 cases of grade 4 bone marrow suppression, which were reversed and relieved after active symptomatic treatment. The median of CD20+B lymphocytes in the peripheral blood of 9 patients before and after chemotherapy was 11.6% and 0.0% respectively, with a statistically significant difference (Z=2.666, P=0.008). The median of IgG level in the peripheral blood of 11 patients before and after chemotherapy was 10.35 g/L and 8.56 g/L respectively, with a statistically significant difference (Z=2.312, P=0.021). Conclusion The chemotherapy regimen based on domestic rituximab has better short-term efficacy and safety in the treatment of newly diagnosed DLBCL, which is more economical than the original rituximab, and the changes of peripheral blood IgG and CD20+B lymphocytes also reflect the targeted therapeutic effect of domestic rituximab.
keywords: Diffuse large B-cell lymphoma Domestic rituximab Short term curative effect Adverse reaction
文章编号： 中图分类号：R733.4 文献标志码：B
基金项目:国家自然科学基金（81670179）；安徽省教育厅高校自然科学研究项目（KJ2021A0324）
| Author Name | Affiliation |
| PAN Ying, WU Fan, QIN Hui, LI Yin-wei, ZHAI Zhi-min | Department of Hematology, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, China |
引用文本：
潘莹，吴凡，秦慧，李迎伟，翟志敏.国产利妥昔单抗治疗初诊弥漫性大B细胞淋巴瘤的近期疗效及安全性[J].中国临床研究,2022,35(9):1301-1304.
潘莹，吴凡，秦慧，李迎伟，翟志敏.国产利妥昔单抗治疗初诊弥漫性大B细胞淋巴瘤的近期疗效及安全性[J].中国临床研究,2022,35(9):1301-1304.